TL;DR
Get smart everyday buys delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Sobi’s Nomination Committee has proposed Börje Ekholm for election as a board member and chair at the company’s 2027 Annual General Meeting. Current chair David Meek will serve through May 2027 and has decided not to stand for re-election.
The Nomination Committee of Swedish biopharmaceutical company Sobi has proposed that Börje Ekholm be elected as a board member and chair at the company’s 2027 Annual General Meeting. The proposal follows current chair David Meek’s decision not to seek re-election; Meek is expected to remain in the role through May 2027.
The proposal is a nomination, not a completed appointment. Sobi shareholders will consider Ekholm’s election at the 2027 AGM. The company said the Nomination Committee will publish its full proposals ahead of the meeting; the announcement does not give the AGM date.
Meek has served on Sobi’s board and as chair since December 2024. According to the company’s announcement, he will continue as chair for the rest of his term, through May 2027. Sobi credited his tenure with growth and shareholder returns, expanded access to medicines through launches and indication extensions, and a strengthened clinical development pipeline. Those assessments were made by the company, rather than presented as independently assessed outcomes.
Ekholm brings more than 30 years of experience in technology, investment management and international business leadership, according to Sobi. He recently stepped down as chief executive of Ericsson and previously led Patricia Industries and Investor AB. He currently chairs Trimble and is due to join Nasdaq’s board on November 1, 2026. His past board positions include Alibaba, Husqvarna, Nasdaq, Scania and WM Data.
A Leadership Change at Sobi
The proposal points to a planned change in Sobi’s board leadership, while leaving the decision with shareholders. The chair leads the board’s work overseeing company strategy and management, making the appointment relevant to investors and others following Sobi’s direction. The announcement does not describe a change to the company’s operating leadership or set out a new strategy.
Ekholm’s prior connection to Sobi is a notable part of the nomination. Sobi said that while he was CEO of Investor AB, he was involved in the creation of Sobi through the merger of Biovitrum and Swedish Orphan International and worked with the company from an owner’s perspective. The committee cited his global leadership and board experience and familiarity with Sobi as reasons for proposing him.
The transition is not immediate: Meek is slated to continue until May 2027, and Ekholm’s proposed role depends on a shareholder vote. Until then, the announcement signals the committee’s preferred successor rather than a change already in effect.
Products Worth Considering
Apple MacBook Pro 14 (2021) with M1 Max, 64 GB RAM, 2 TB SSD, Silver
Logitech MX Mechanical Full-Size Wireless Mechanical Keyboard, Tactile Quiet Switches, Backlit Keys, Bluetooth, USB-C, Multi-Device, Graphit
Ledger Stax Crypto Wallet with Touchscreen
As an affiliate, we earn on qualifying purchases.
Meek’s Term and Ekholm’s Sobi Ties
Sobi is a Stockholm-listed biopharmaceutical company focused on medicines for rare diseases. The company said it had approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia, and reported 2025 revenue of SEK 28 billion. These figures provide a snapshot of the company’s scale; they do not indicate the reason for the board nomination.
Meek became chair in December 2024. In announcing his decision not to stand again, Sobi said he would continue in the position through May 2027. The Nomination Committee’s proposal therefore sets out a planned successor for the next AGM rather than an immediate departure or vacancy.
Ekholm’s background spans senior executive and board roles. Besides his former posts at Ericsson, Investor AB and Patricia Industries, Sobi listed board experience at several international companies and advisory roles with Mars and Ericsson’s chief executive. His involvement with the formation of Sobi dates to his time at Investor, giving him a prior relationship with the company alongside his broader leadership experience.
Ekholm has not yet been elected to Sobi’s board or appointed chair. Shareholders are due to vote at the 2027 AGM, but the announcement does not provide the meeting date, details of the election process, or the full slate of candidates. The Nomination Committee said it will publish its complete proposals before the meeting.
Sobi’s announcement does not explain whether Meek’s decision was driven by a particular event or disclose further details about the process that led to Ekholm’s nomination. Nor does it describe any planned change in board strategy, company priorities or executive management. Those matters remain unconfirmed by the material released.
The 2027 AGM Decision
The next stated milestone is publication of the Nomination Committee’s complete proposals ahead of Sobi’s 2027 AGM. Shareholders will then decide whether to elect Ekholm as a board member and chair. Until that vote, Meek is expected to remain chair through May 2027, in line with his current term as described by the company.
Further information to watch for includes the AGM date, the committee’s full nominations and any additional details Sobi releases about the board’s composition. The current announcement establishes the proposed succession but does not confirm the outcome of the vote.
Key Questions
Has Börje Ekholm become Sobi’s chair?
No. Sobi’s Nomination Committee has proposed Ekholm for election as a board member and chair. Shareholders must vote on the proposal at the 2027 AGM.
When will shareholders vote?
The vote is expected at Sobi’s 2027 Annual General Meeting. The announcement does not give the meeting date; the committee said it will publish its complete proposals ahead of the AGM.
How long will David Meek remain chair?
Sobi said Meek will continue as chair for the remainder of his term, through May 2027. He has decided not to stand for re-election at the 2027 AGM.
Why did the committee propose Ekholm?
Committee chair Daniel Nodhäll cited Ekholm’s global leadership and board experience and familiarity with Sobi. The company also noted his involvement in Sobi’s formation while he was at Investor AB.
Source: prnewswire.com
